{"id":"NCT00943397","sponsor":"Organon and Co","briefTitle":"Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)","officialTitle":"A Multicenter, Open-Label, Controlled, Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-04","primaryCompletion":"2001-10","completion":"2001-11","firstPosted":"2009-07-22","resultsPosted":"2010-06-17","lastUpdate":"2022-02-03"},"enrollment":190,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":["Montelukast"]},{"type":"DRUG","name":"Comparator: Usual Care","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Patients were treated with either montelukast 4 mg oral granules or usual care. Patients who completed Protocol MK0476-176-01 (NCT00943683) had the option to enroll in this study. Additionally, patients with asthma who were 6 to 11 months of age and who had not participated in Protocol MK0476-176-01, could also enroll.","primaryOutcome":{"measure":"Number of Clinical Adverse Experiences (CAEs) Reported by Patients With up to 52 Weeks of Treatment","timeFrame":"Up to 52 weeks of treatment","effectByArm":[{"arm":"Usual Care","deltaMin":31,"sd":null},{"arm":"Montelukast","deltaMin":156,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19449366"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":32},"commonTop":["Upper Respiratory Infection","Asthma","Pharyngitis","Otitis Media","Diarrhea"]}}